These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 19014549

  • 1. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease.
    Calverley PM, Rennard S, Nelson HS, Karpel JP, Abbate EH, Stryszak P, Staudinger H.
    Respir Res; 2008 Nov 13; 9(1):73. PubMed ID: 19014549
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
    D'Urzo A, Karpel JP, Busse WW, Boulet LP, Monahan ME, Lutsky B, Staudinger H.
    Curr Med Res Opin; 2005 Aug 13; 21(8):1281-9. PubMed ID: 16083538
    [Abstract] [Full Text] [Related]

  • 3. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
    Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012 Aug 13; 7():57-71. PubMed ID: 22334769
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
    Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012 Aug 13; 7():73-86. PubMed ID: 22334770
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
    Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012 Aug 13; 7():43-55. PubMed ID: 22334768
    [Abstract] [Full Text] [Related]

  • 6. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.
    Noonan M, Karpel JP, Bensch GW, Ramsdell JW, Webb DR, Nolop KB, Lutsky BN.
    Ann Allergy Asthma Immunol; 2001 Jan 13; 86(1):36-43. PubMed ID: 11206236
    [Abstract] [Full Text] [Related]

  • 7. Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma.
    Karpel JP, Nelson H.
    Curr Med Res Opin; 2007 Nov 13; 23(11):2897-911. PubMed ID: 17922978
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma.
    Noonan M, Leflein J, Corren J, Staudinger H.
    BMC Pediatr; 2009 Jul 13; 9():43. PubMed ID: 19594937
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
    Kosoglou T, Hubbell J, Xuan F, Cutler DL, Meehan AG, Kantesaria B, Wittmer BA.
    Int J Chron Obstruct Pulmon Dis; 2013 Jul 13; 8():107-16. PubMed ID: 23525511
    [Abstract] [Full Text] [Related]

  • 10. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma.
    Corren J, Berkowitz R, Murray JJ, Prenner B.
    Int J Clin Pract; 2003 Sep 13; 57(7):567-72. PubMed ID: 14529054
    [Abstract] [Full Text] [Related]

  • 11. Effects of mometasone furoate administered via a dry powder inhaler once daily in the evening on nocturnal lung function and sleep parameters in patients with moderate persistent asthma: a randomized, double-blind, placebo-controlled pilot study.
    Krouse JH, Krouse HJ, Janisse JJ.
    Clin Drug Investig; 2009 Sep 13; 29(1):51-8. PubMed ID: 19067474
    [Abstract] [Full Text] [Related]

  • 12. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
    Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM.
    Chest; 2000 Dec 13; 118(6):1538-46. PubMed ID: 11115437
    [Abstract] [Full Text] [Related]

  • 13. Mometasone furoate (MF) improves lung function in pediatric asthma: A double-blind, randomized controlled dose-ranging trial of MF metered-dose inhaler.
    Amar NJ, Shekar T, Varnell TA, Mehta A, Philip G.
    Pediatr Pulmonol; 2017 Mar 13; 52(3):310-318. PubMed ID: 27740721
    [Abstract] [Full Text] [Related]

  • 14. Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler.
    Zetterström O, Dahl R, Lindqvist A, Olsson P.
    Respir Med; 2008 Oct 13; 102(10):1406-11. PubMed ID: 18640826
    [Abstract] [Full Text] [Related]

  • 15. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study.
    Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H.
    BMC Pulm Med; 2010 Jan 05; 10():1. PubMed ID: 20051135
    [Abstract] [Full Text] [Related]

  • 16. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.
    Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE.
    J Allergy Clin Immunol; 2000 Sep 05; 106(3):485-92. PubMed ID: 10984368
    [Abstract] [Full Text] [Related]

  • 17. Inhaled mometasone furoate improves health-related quality of life in patients with persistent asthma.
    Karpel J, D'urzo A, Lockey RF.
    J Asthma; 2008 Nov 05; 45(9):747-53. PubMed ID: 18972289
    [Abstract] [Full Text] [Related]

  • 18. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
    O'Connor B, Bonnaud G, Haahtela T, Luna JM, Querfurt H, Wegener T, Lutsky BN.
    Ann Allergy Asthma Immunol; 2001 Apr 05; 86(4):397-404. PubMed ID: 11345282
    [Abstract] [Full Text] [Related]

  • 19. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma.
    Nayak AS, Banov C, Corren J, Feinstein BK, Floreani A, Friedman BF, Goldsobel A, Gottschlich GM, Hannaway PJ, Lampl KL, Lapidus RJ, Lawrence M, Lumry W, Munk Z, Pearlman D, Scardella AT, Schenkel EJ, Segal AT, Segall N, Silverman B, Shneyer L, Nolop KB, Harrison JE.
    Ann Allergy Asthma Immunol; 2000 Apr 05; 84(4):417-24. PubMed ID: 10795650
    [Abstract] [Full Text] [Related]

  • 20. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
    Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG.
    Chest; 2005 Jul 05; 128(1):70-7. PubMed ID: 16002918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.